TLDR
The SEC has again postponed its innovation exemption for tokenized assets, keeping US onchain securities trading stuck in a gray zone for now.
- The innovation exemption, meant to ease rules for tokenization projects, remains on hold as the SEC defers to ongoing CLARITY Act negotiations.
- The delay slows US?based tokenized stocks and RWAs, even as tokenization platforms and funds keep growing under other, narrower approvals.
- Regulation Crypto and the CLARITY Act now carry most of the near?term regulatory momentum, and their next steps will shape when tokenization gets real clarity.
Deep Dive
1. What Was Delayed
The SEC has again postponed publishing its innovation exemption for tokenization, according to coverage citing SEC watchers and industry commentators. The exemption is intended to create a lighter, tailored regime for certain tokenization projects so they can operate with clearer rules and reduced compliance friction.
A recent explainer notes that the SEC is holding back partly to avoid cutting across Section 10505 of the CLARITY Act, which explicitly addresses tokenization and was drafted as the main legislative guardrail for this area. By pausing, the SEC is signaling that it does not want its own exemption to undermine a potential congressional compromise on how tokenized assets should be treated.
US regulators are acknowledging tokenizations importance, but they are prioritizing alignment with Congress over moving fast on a standalone exemption.
2. Why It Matters For Onchain Markets
Industry pieces describe the innovation exemption as the missing bridge between todays pilots and full 24/7 trading of tokenized stocks on public blockchains, with fractional shares and near?instant settlement on chains like Solana and Base. Without it, much of that activity stays offshore or in limited US test environments, and platforms must rely on bespoke approvals rather than a clear rule set.
At the same time, tokenization is not frozen. Securitize reports record tokenized assets under management and growing transaction volumes, even as it waits for broader regulatory progress. Franklin Templeton recently secured an SEC no?action letter letting its funds use a tokenized government money fund for cash and collateral, showing that specific tokenized products can move forward under tailored relief.
The big unlock for fully onchain US equities is delayed, but niche tokenized products and institutional pilots are still inching ahead under case?by?case approvals.
3. What To Watch Next
While the tokenization exemption stalls, the SEC is pressing ahead with a public meeting on Regulation Crypto Assets, a proposed framework to create exemptions and a safe harbor for crypto fundraising. Analysts see this as the primary near?term path to formal crypto rules. At the same time, the CLARITY Act remains in play in Congress, with upcoming votes expected to determine whether lawmakers set broader digital?asset guardrails.
Commentary from both regulators and market participants suggests that the eventual innovation exemption, if adopted, will likely be shaped by feedback from these processes. The timing and content of Regulation Crypto, the fate of the CLARITY Act, and any future SEC open meetings mentioning tokenization are the key signals for when US tokenized stocks and RWAs might leave the gray zone.
For tokenization projects, the practical timeline now hinges on how quickly Regulation Crypto moves through the rulemaking cycle and whether Congress advances the CLARITY Acts tokenization provisions.
Conclusion
The SECs renewed delay on the innovation exemption keeps US tokenization in regulatory limbo, even as specific tokenized funds and platforms gain narrow approvals. The real momentum is shifting to broader crypto rulemaking and legislation, which will likely define the boundaries within which a future tokenization exemption can safely operate. For crypto users and builders, the path to mainstream onchain stocks is still open, but it runs through Regulation Crypto, the CLARITY Act, and continued regulatory experimentation rather than a single rapid breakthrough.
